Lakefront Biotherapeutics/$LKFT
1D1W1MYTD1Y5YMAX
Capital at risk
About Lakefront Biotherapeutics
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
- Ticker
- $LKFT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 196
- Headquarters
- Mechelen, Belgium
- Website
- lakefrontbio.com
LKFT Metrics
BasicAdvanced
$1.9B
2.89
$10.15
0.12
-
Price and volume
Market cap
$1.9B
Beta
0.12
52-week high
$37.78
52-week low
$25.68
Average daily volume
289K
Financial strength
Current ratio
32.839
Quick ratio
32.647
Long term debt to equity
0.001
Total debt to equity
0.002
Interest coverage (TTM)
664.53%
Profitability
EBITDA (TTM)
738.89
Gross margin (TTM)
73.43%
Net profit margin (TTM)
60.23%
Operating margin (TTM)
64.99%
Effective tax rate (TTM)
-2.90%
Revenue per employee (TTM)
$5,682,860
Management effectiveness
Return on assets (TTM)
9.93%
Return on equity (TTM)
20.12%
Valuation
Price to earnings (TTM)
2.893
Price to revenue (TTM)
1.742
Price to book
0.52
Price to tangible book (TTM)
0.67
Price to free cash flow (TTM)
-7.428
Free cash flow yield (TTM)
-13.46%
Free cash flow per share (TTM)
-3.954
Growth
Revenue change (TTM)
259.40%
Earnings per share change (TTM)
-308.93%
3-year revenue growth (CAGR)
125.91%
10-year revenue growth (CAGR)
29.90%
3-year earnings per share growth (CAGR)
55.61%
10-year earnings per share growth (CAGR)
22.01%
Bulls say / Bears say
Gamgertamig is progressing towards a nearer-term value inflection: Lakefront says its Phase 1b studies are enrolling, early data show durability and consistent responses, and registration studies in ITP and AIHA are planned for 2027. (Lakefront Biotherapeutics, StockAnalysis)
Gamgertamig has received FDA Fast Track and Orphan Drug designations for ITP and AIHA, with Orphan Drug status also granted in pemphigus. Gilead is sharing development responsibilities and will lead registration and commercialisation, which could reduce Lakefront’s execution burden. (Lakefront Biotherapeutics, Lakefront Biotherapeutics)
Lakefront expects to end 2026 with €1.975 billion to €2.05 billion in cash and financial investments, even after the Ouro transaction and a €50 million share buyback. This provides substantial funding for development and further business development without an immediate need to raise equity. (Lakefront Biotherapeutics, Lakefront Biotherapeutics)
GLPG3667 suffered a meaningful clinical setback: the GALACELA study missed its primary endpoint at 32 weeks and the comparable secondary endpoint at 48 weeks. Lakefront is now evaluating strategic options for the programme. (Lakefront Biotherapeutics)
Gamgertamig remains unproven, and its route to approval is not yet fully defined. Lakefront still needs to agree the registration-trial designs and patient numbers with regulators, while further data are only expected towards the end of 2026. (StockAnalysis, Lakefront Biotherapeutics)
The investment case is heavily dependent on one partnered lead asset and on Gilead’s execution. Gilead holds worldwide commercialisation rights outside Keymed’s territories, while Lakefront receives tiered royalties of 20% to 23%, so Lakefront will capture only part of any eventual product value. (Lakefront Biotherapeutics, Lakefront Biotherapeutics)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
LKFT Financial Performance
Revenues and expenses
LKFT Earnings Performance
Company profitability
Upcoming events
No upcoming events
LKFT News
AllArticlesVideos
Funds containing LKFT
AllUSDGBP
Fund name | Fund size | $LKFT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.03% |
Vanguard ESG Global All Cap£V3AB | £905M | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.